Filing Flows › Sarepta Therapeutics (SRPT) › Q1 2025
Sarepta Therapeutics (SRPT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Sarepta Therapeutics (SRPT) reported revenue of $745M for the first quarter 2025 (Q1 2025), +80% from a year earlier and +13% from the quarter before. Operating margin was -40.3%, net loss $448M (60.1% of revenue).
Sarepta Therapeutics, Q1 2025: revenue $745M (+80% year over year), operating margin -40.3%, net loss $448M, operating cash flow −$583M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $745M | +13% | +80% |
| Operating profit | −$300M | — | — |
| Net earnings | −$448M | — | — |
| Operating cash flow | −$583M | — | — |
What changed
Revenue was $744.9M in Q1 2025, up 80% year over year and up 13% from the previous quarter.
Gross margin was 63.6%, down 11.1 points from a year earlier. Operating costs exceeded revenue by $300.4M, an operating margin of -40.3%. Operating expenses grew 183% against revenue growth of 80%. The quarter ended with a net loss of $447.5M, after a profit of $159.0M the previous quarter.
Operating cash flow was −$583.4M. Non-cash charges added back $10.0M of depreciation and amortization and $41.4M of share-based compensation. Working capital and other items used $187.3M. Capital expenditures of $43.7M exceeded it, leaving free cash flow of −$627.1M.
Questions
What was Sarepta Therapeutics' revenue in the first quarter 2025?
Sarepta Therapeutics (SRPT) reported revenue of $745M for the first quarter 2025 (Q1 2025), +80% from a year earlier and +13% from the quarter before.
Was Sarepta Therapeutics profitable in the first quarter 2025?
Operating loss was $300M (-40.3% of revenue) and net loss $448M.